Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02759887 · ClinicalTrials.gov registry record · NA

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

A NA study of Down Syndrome and Alzheimer's Dementia, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

Completed
Registry status
NA
Development phase
19
Enrollment target
1
Study location

NCT02759887: Completed NA study of Down Syndrome and Alzheimer's Dementia, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

NCT02759887 is a NA study of Down Syndrome and Alzheimer's Dementia that has completed, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 19 participants, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02759887, a NA study of Down Syndrome and Alzheimer's Dementia, has completed, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

COMPLETED
Registry status
NA
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

In order to treat individuals with Down syndrome (DS) better and more efficiently and to gain more insights on its relation to Alzheimer's disease (AD), a comprehensive understanding is needed for its progression in the early or preclinical phase using various biomarkers. DS is a significant risk factor for the early development of AD, with plaques and tangles typically developing by age 35. A better understanding is needed of early markers of the disease in DS patients. Additionally the DS population represents a unique group - due to this elevated risk for AD - to examine biomarkers that may translate in general outside of the DS population to individuals at risk for developing late onset AD. In this proposal, the researchers will assess the longitudinal changes of various biomarkers in a cohort of individuals similar in design to the cross-sectional sectional study in the preliminary data.

Primary Outcome

The researchers will use multi-modal partial least squares (MMPLS) to integrate the volumetric MRI, tau PET, FDG PET and florbetapir PET data and investigate the potential for increased sensitivity to examine the longitudinal changes related to both brain structure and fibrillar amyloid depositions. The MMPLS based subject scores, which is free from multiple comparisons, will be the primary measure integrating information from imaging modalities. The combined primary measures will be used each t

Interventions

  • PROCEDURE MRI
  • PROCEDURE biospecimen collection
  • OTHER cognitive assessments
  • OTHER caregiver questionnaire
  • PROCEDURE Florbetapir F18 imaging

Study Locations (1)

Arizona

  • St. Joseph's Hospital and Medical Center - Phoenix

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2016-11
Est. Completion 2018-12
Phase NA

What the finished NCT02759887 record still lists

NCT02759887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Down Syndrome appearing as the primary indexed condition, and to 5 interventions - of which MRI is the first listed.

NCT02759887 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT02759887 about?

NCT02759887 is a clinical study titled "Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)". In order to treat individuals with Down syndrome (DS) better and more efficiently and to gain more insights on its relation to Alzheimer's disease (AD), a comprehensive understanding is needed for its progression in the early or preclinical phase using various biomarkers. DS is a significant risk fa...

What is the current status of trial NCT02759887?

This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2016-11. Estimated completion is 2018-12.

What conditions does trial NCT02759887 study?

This clinical trial studies the following conditions: Down Syndrome, Alzheimer's Dementia.

What interventions are being tested in trial NCT02759887?

The interventions under investigation include: MRI (PROCEDURE), biospecimen collection (PROCEDURE), cognitive assessments (OTHER), caregiver questionnaire (OTHER), Florbetapir F18 imaging (PROCEDURE).

Who is sponsoring clinical trial NCT02759887?

This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02759887 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Down Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02759887's enrollment target sits among peer trials

19 47th of 54 higher than 7 of 54 other Down Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Down Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02759887, the US trial registry maintained by the National Library of Medicine. NCT02759887 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.